EMAIL THIS PAGE TO A FRIEND

Molecular cancer therapeutics

Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.


PMID 25976679

Abstract

Aromatase inhibitors are effective drugs that reduce or eliminate hormone-sensitive breast cancer. However, despite their efficacy, resistance to these drugs can occur in some patients. The INrf2 (Keap1):Nrf2 complex serves as a sensor of drug/radiation-induced oxidative/electrophilic stress. INrf2 constitutively suppresses Nrf2 by functioning as an adapter protein for the Cul3/Rbx1-mediated ubiquitination/degradation of Nrf2. Upon stress, Nrf2 dissociates from INrf2, is stabilized, translocates to the nucleus, and coordinately induces a battery of cytoprotective gene expression. Current studies investigated the role of Nrf2 in aromatase inhibitor resistance. RT-PCR and immunoblot assays showed that aromatase inhibitor-resistant breast cancer LTLTCa and AnaR cells express lower INrf2 and higher Nrf2 protein levels, as compared with drug-sensitive MCF-7Ca and AC1 cells, respectively. The increase in Nrf2 was due to lower ubiquitination/degradation of Nrf2 in aromatase inhibitor-resistant cells. Higher Nrf2-mediated levels of biotransformation enzymes, drug transporters, and antiapoptotic proteins contributed to reduced efficacy of drugs and aversion to apoptosis that led to drug resistance. shRNA inhibition of Nrf2 in LTLTCa (LTLTCa-Nrf2KD) cells reduced resistance and sensitized cells to aromatase inhibitor exemestane. Interestingly, LTLTCa-Nrf2KD cells also showed reduced levels of aldehyde dehydrogenase, a marker of tumor-initiating cells and significantly decreased mammosphere formation, as compared with LTLTCa-Vector control cells. The results together suggest that persistent aromatase inhibitor treatment downregulated INrf2 leading to higher expression of Nrf2 and Nrf2-regulated cytoprotective proteins that resulted in increased aromatase inhibitor drug resistance. These findings provide a rationale for the development of Nrf2 inhibitors to overcome resistance and increase efficacy of aromatase inhibitors.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2500010
Anti-ABCC1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA002380
Anti-ABCC1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, Ab1
SAB2100010
Anti-ABCC1 antibody produced in rabbit, affinity isolated antibody
SAB2501329
Anti-ABCC4 (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
HPA002476
Anti-ABCC4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB1406822
Anti-ABCG2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4300689
Anti-ABCG2 antibody produced in rabbit, affinity isolated antibody
B9304 Anti-Bcl-x antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB3500349
Anti-Bcl-xL antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
GW21157 Anti-BCL2L1 antibody produced in chicken, affinity isolated antibody, buffered aqueous solution
AV02008
Anti-BCL2L1 antibody produced in rabbit, affinity isolated antibody
AV30475
Anti-BCL2L1 antibody produced in rabbit, IgG fraction of antiserum
SAB2103893
Anti-BCL2L1, (N-terminal) antibody produced in rabbit, affinity isolated antibody
B7185
Anti-Breast Cancer Resistance Protein antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV34116
Anti-G22P1 (AB1) antibody produced in rabbit, IgG fraction of antiserum
AV34117
Anti-G22P1 (AB2) antibody produced in rabbit, IgG fraction of antiserum
AV34727
Anti-KEAP1 (AB1) antibody produced in rabbit, affinity isolated antibody
AV38981
Anti-KEAP1 (AB2) antibody produced in rabbit, affinity isolated antibody
SAB2501696
Anti-KEAP1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
K3144
Anti-Keap1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA005558
Anti-KEAP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
AV34728
Anti-KEAP1 antibody produced in rabbit, IgG fraction of antiserum, lyophilized powder
SAB1306517
ANTI-KU70 (CENTER) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
K4763 Anti-Ku70 antibody produced in rabbit, affinity isolated antibody, ammonium sulfate suspension
SAB4501057
Anti-KU70, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4503096
Anti-KU70, C-Terminal antibody produced in rabbit, affinity isolated antibody
M8434 Anti-Mcl-1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB3500291
Anti-Mcl-1 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
HPA031125 Anti-MCL1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4501843
Anti-MCL1 antibody produced in rabbit, affinity isolated antibody